The industry does not do a very good job of letting providers know there are ways to cover risk or protect against it. Better educating physicians on this would help improve uptake of value-based care models, said Mike Fazio, senior vice president of client services, Archway Health.
The industry does not do a very good job of letting providers know there are ways to cover risk or protect against it. Better educating physicians on this would help improve uptake of value-based care models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
Studies have shown that providers don’t see alternative payment model uptake happening very quickly. What can be done to improve participation and move the industry more quickly to value-based care?
CMS does a great job at creating well-defined models that are, like OCM [Oncology Care Model] and BPCI [Bundled Payments for Care Improvement] Advanced. But they are complex and highly regulatory. So, understanding the rules and the complexity of the model takes a long time. And so, walking providers through that slowly, we found helps them understand and be willing to participate in something like a voluntary model like OCM.
And so, I think payers and employers could do a better job in following CMS’ lead in offering contracts like that to the market. And that’s been slow. They’ve kind of been on the sidelines and CMS has been leading the way with things like OCM. So, it’s getting practices and hospitals to understand what it really means to be in a model and it’s ok to walk slowly from a beginning and try not to make it too cumbersome to begin and usually that helps when you work with them to understand it.
And then the movement to risk is a big factor in participation. So, getting providers to understand that there are partners that they can work with to either cover that risk or protect against risk and risk mitigation tools is important so that it’s [not], “I can’t do this model because we can’t bear the risk or we’re not risk tolerant.” And so, I think the industry can just do a better job, at least on the vendor side with getting practices to understand those components of it.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More